指南与共识泌尿男性生殖肿瘤

前列腺癌筛查MRI国际共识:PRISM推荐

Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations.
指南 / 共识 · JAMA Oncol · 2026-01-01

该国际共识基于系统综述与荟萃分析(6项研究、1919例受试者)及RAND/UCLA appropriateness方法,由21名专家制定前列腺癌筛查MRI的采集、解读与报告推荐,涵盖简化非增强方案、分期门控报告及质量保证标准。

要点

  • 筛查MRI推荐用于预期寿命>10年、50-70岁男性,黑人男性从45岁起。
  • 采用仅含T2加权与扩散加权成像的非增强MRI,最大采集时间15分钟。
  • 推荐分期门控(两步法)报告,重复筛查按患者特征风险分层。

核心结论

  • PRISM共识为前列腺癌筛查中MRI的应用提供标准化专家指导,包括简化非增强方案、筛查间隔、分期门控报告和质量保证标准。

研究设计与样本

  • 系统综述与荟萃分析纳入6项研究共1919例参与者,其中1426例接受 upfront 筛查MRI,多数研究使用3.0-T非增强MRI。
  • 通过RAND/UCLA appropriateness方法开展共识,21名专家(8名泌尿外科、11名放射科、2名病理科,来自6个国家)参与,323条共识声明中235条(72.8%)达成一致。

主要发现

  • 汇总活检推荐率为19.2%(95%CI 11.7-26.7),GG2及以上前列腺癌检出率为6.0%(95%CI 3.1-9.0),GG1癌检出率为1.4%(95%CI 0.7-2.2)。
  • GG2及以上癌的阳性预测值为36.3%(95%CI 21.1-51.4)。

关键数值与推荐

  • 若将MRI用于筛查,推荐用于预期寿命大于10年且年龄50至70岁的男性,黑人男性从45岁起。
  • 筛查MRI应在PSA检测后进行,但关于最佳PSA阈值未达成共识。
  • 仅含T2加权和扩散加权成像的非增强MRI被认为合适,最大可接受采集时间为15分钟。
  • 推荐分期门控(两步法)报告:仅在轴位T2加权和高b值扩散成像(第一步)发现一致局灶性病变时,才揭示所有MRI序列(第二步)。
  • 重复筛查应根据患者特征进行风险分层;筛查MRI应仅在认证中心由满足最低报告要求和质量标准的放射科医生执行。

临床怎么用

  • 在筛查项目中,对符合年龄和预期寿命条件的男性,可先进行PSA检测,再行简化非增强MRI(T2WI+DWI,≤15分钟)。
  • 采用分期门控报告模式,先评估轴位T2WI和高b值DWI,发现一致局灶性病变后再解读其他序列。
  • 重复筛查间隔应基于患者特征进行风险分层,而非固定间隔。
  • 筛查MRI应在认证中心由符合最低报告和质量标准的放射科医生执行。

局限性

  • 系统综述仅纳入6项研究,样本量有限(1919例参与者)。
  • 关于最佳PSA阈值未达成共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Magnetic resonance imaging (MRI) is routinely used in prostate cancer diagnosis, but there is uncertainty about its optimal use in population-level screening. OBJECTIVE: To provide consensus recommendations on the acquisition, interpretation, and reporting of prostate MRI for cancer screening. EVIDENCE REVIEW: A systematic review and meta-analysis of randomized clinical trials and prospective cohort studies evaluating MRI for prostate cancer screening was conducted for these international consensus recommendations. A search of PubMed, CENTRAL, Scopus, Web of Science, and ClinicalTrials.gov, citation searching, and consultation with experts was performed in September 2024. Studies performing upfront MRI for the purpose of prostate cancer screening were included. FINDINGS: A total of 6 studies were identified and included 1919 participants, of whom 1426 underwent upfront screening MRI. Most studies used 3.0-T non-contrast-enhanced MRI. The pooled biopsy recommendation rate was 19.2% (95% CI, 11.7-26.7), with grade group (GG) 2 or higher prostate cancer detection of 6.0% (95% CI, 3.1-9.0) and GG1 cancer detection of 1.4% (95% CI, 0.7-2.2). The positive predictive value for GG2 or higher cancer was 36.3% (95% CI, 21.1-51.4). Findings informed a RAND/UCLA Appropriateness Method consensus exercise used to produce the Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM) recommendations. A total of 21 experts (8 urologists, 11 radiologists, and 2 pathologists from 6 countries) were included on the panel. Among 323 consensus statements, 235 (72.8%) reached agreement. If MRI is used in screening, it is recommended for men with an estimated life expectancy greater than 10 years and aged 50 to 70 years or from age 45 years in Black men. Screening MRI should be performed in men after a prostate-specific antigen (PSA) test, but there was no consensus on the optimal PSA threshold. Non-contrast-enhanced MRI with only T2-weighted and diffusion-weighted imaging was considered appropriate, with a maximum acceptable acquisition time of 15 minutes. The stage-gated (2-step) approach to reporting, where all MRI sequences are only revealed (second step) if a concordant focal lesion is identified on axial T2-weighted and high b-value diffusion imaging (first step), was recommended. Repeat screening should be risk stratified according to patient characteristics. Screening MRI should only be performed in accredited centers with radiologists meeting minimum reporting requirements and quality standards. CONCLUSIONS AND RELEVANCE: The PRISM consensus recommendations provide standardized expert guidance on the use of MRI in prostate cancer screening trials and future screening programs, including abbreviated non-contrast-enhanced MRI protocols, recommended screening intervals, stage-gated reporting, and quality assurance standards.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Mayor N, Light A, Gopalakrishnan A, et al. Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM): International Consensus Recommendations. JAMA Oncol. 2026. PMID: 42275039. doi:10.1001/jamaoncol.2026.1711

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。